Chronic Obstructive Pulmonary Disease

Detailed Overview

COPD encompasses two main phenotypes: emphysema (alveolar destruction) and chronic bronchitis (small airway inflammation with mucus hypersecretion). The hallmark is irreversible airflow obstruction. Patients suffer from progressive dyspnea and exacerbations, predominantly triggered by viral or bacterial infections. Smoking cessation is the only intervention that definitively alters the natural disease course.

Epidemiology & Demographics

Third leading cause of death worldwide. Global prevalence is ~10-12% in adults over 40. Equal prevalence in men and women in developed nations.

Etiological Mechanism

Long-term inhalation of noxious particles, predominantly cigarette smoke, or genetic deficiency of alpha-1 antitrypsin.

Primary Causes

Cigarette smoking (80-90% of cases), indoor biomass fuel exposure (developing nations).

• Tobacco Smoke: Pack-year history >20 strongly correlates with COPD development.
• Alpha-1 Antitrypsin Deficiency: Genetic condition causing early-onset panacinar emphysema, often affecting lower lobes.

Noxious particles trigger macrophage and neutrophil infiltration in the lungs. In chronic bronchitis, neutrophils release elastase and mucin-stimulating cytokines, causing goblet cell hyperplasia and mucus plugging of bronchioles. In emphysema, the imbalance of proteases (overactive) and antiproteases (depleted) destroys the alveolar septa. This reduces elastic recoil, causing small airways to collapse during exhalation, trapping air (hyperinflation) and reducing the surface area for gas exchange.

Characteristic Clinical Presentation

• Progressive Dyspnea: Shortness of breath that is worse with exertion and worsens over time.
• Chronic Cough: Often productive of sputum, historically worse in the morning ('smoker's cough').

Physical Examination Signs

• Barrel Chest
• Prolonged Expiratory Phase
• Use of Accessory Muscles

• Cor Pulmonale: Right ventricular failure due to hypoxic pulmonary vasoconstriction and pulmonary hypertension.
• Secondary Polycythemia: Increased RBC mass (Hct >55%) as a physiologic response to chronic hypoxemia.

Diagnostic Criteria & Guidelines

Spirometry is required for diagnosis: Post-bronchodilator FEV1/FVC ratio < 0.70 confirms persistent airflow limitation.

Differential Diagnosis

• Asthma (reversible obstruction)
• Congestive Heart Failure
• Bronchiectasis

Laboratory Tests & Biomarkers

• Arterial Blood Gas (ABG): May show chronic compensated respiratory acidosis (pH normal, elevated pCO2 >45, elevated HCO3).
• Alpha-1 Antitrypsin Level: Test in all patients diagnosed <45 years old or with lower lobe emphysema. <11 micromol/L is diagnostic.

Imaging Modalities & Findings

• CXR:

• GOLD 1
  FEV1 >= 80% predicted.
• GOLD 4
  FEV1 < 30% predicted, often accompanied by chronic respiratory failure.

Second-Line & Adjunctive Therapy

Triple therapy (LAMA + LABA + Inhaled Corticosteroid like Fluticasone) for frequent exacerbators with blood eosinophils >300 cells/uL. Roflumilast (PDE4 inhibitor) for severe chronic bronchitis.

Surgical & Procedural Management

Lung Volume Reduction Surgery (LVRS) or endobronchial valves for severe upper-lobe predominant emphysema. Lung transplantation for refractory end-stage disease.

Recommended Lifestyle Changes

• Pulmonary rehabilitation programs to improve exercise tolerance.
• Annual Influenza and Pneumococcal (PCV20) vaccinations.

Patient Counseling & Advice

Inhaler technique is critical; demonstrate and ask for teach-back. Emphasize that smoking cessation stops the accelerated lung function decline.

Follow-Up & Monitoring Schedule

Annual spirometry to track FEV1 decline. Assess inhaler technique and exacerbation frequency every 3-6 months.

Preventive Strategies

Never starting smoking. Occupational dust/chemical hazard avoidance.

Incurable but manageable. BODE index (BMI, Obstruction, Dyspnea, Exercise capacity) predicts 4-year survival.